{
  "ticker": "CABA",
  "company_name": "Cabaletta Bio, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04422912",
      "title": "A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Pemphigus Vulgaris",
      "start_date": "2020-09-29",
      "completion_date": "2029-01",
      "enrollment": 0,
      "sponsor": "Cabaletta Bio"
    },
    {
      "nct_id": "NCT07006805",
      "title": "RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis (MS) - Relapsing-remitting, Progressive Multiple Sclerosis",
      "start_date": "2026-06",
      "completion_date": "2029-10",
      "enrollment": 0,
      "sponsor": "Cabaletta Bio"
    },
    {
      "nct_id": "NCT06359041",
      "title": "RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Generalized Myasthenia Gravis (gMG)",
      "start_date": "2024-12-17",
      "completion_date": "2029-09",
      "enrollment": 0,
      "sponsor": "Cabaletta Bio"
    },
    {
      "nct_id": "NCT06328777",
      "title": "RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Systemic Sclerosis, Scleroderma",
      "start_date": "2024-07-02",
      "completion_date": "2029-07",
      "enrollment": 0,
      "sponsor": "Cabaletta Bio"
    },
    {
      "nct_id": "NCT06154252",
      "title": "RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis",
      "start_date": "2023-12-20",
      "completion_date": "2028-07",
      "enrollment": 0,
      "sponsor": "Cabaletta Bio"
    },
    {
      "nct_id": "NCT06121297",
      "title": "RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Systemic Lupus Erythematosus, Lupus Nephritis",
      "start_date": "2024-02-16",
      "completion_date": "2029-12",
      "enrollment": 0,
      "sponsor": "Cabaletta Bio"
    },
    {
      "nct_id": "NCT05451212",
      "title": "Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "MuSK Myasthenia Gravis",
      "start_date": "2022-11-23",
      "completion_date": "2025-07-24",
      "enrollment": 0,
      "sponsor": "Cabaletta Bio"
    }
  ],
  "summary": {
    "total_trials": 7,
    "by_phase": {
      "PHASE1, PHASE2": 6,
      "PHASE1": 1
    },
    "by_status": {
      "RECRUITING": 5,
      "NOT_YET_RECRUITING": 1,
      "COMPLETED": 1
    },
    "active_trials": 5,
    "completed_trials": 1,
    "conditions": [
      "Generalized Myasthenia Gravis (gMG)",
      "Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis",
      "MuSK Myasthenia Gravis",
      "Pemphigus Vulgaris",
      "Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis (MS) - Relapsing-remitting, Progressive Multiple Sclerosis",
      "Systemic Lupus Erythematosus, Lupus Nephritis",
      "Systemic Sclerosis, Scleroderma"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:16.422713",
    "search_query": "Cabaletta Bio, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Cabaletta+Bio,+Inc."
  }
}